CME Group Inc. is set to introduce a futures contract on the cryptocurrency ether in February 2021. The inclusion will be subject to regulatory approval.
The proposed contract will be cash-settled.
Amid the success of Bitcoin futures and options, CME Group will add Ether futures to its cryptocurrency risk-management solutions. This is expected to offer the clients a tool to trade and hedge this digital currency.
In January 2020, CME launched bitcoin options and options on SOFR.
CME saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on April 30, 2024. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 47 instances where the indicator turned negative. In of the 47 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 64 cases where CME's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
CME moved below its 50-day moving average on April 24, 2024 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for CME crossed bearishly below the 50-day moving average on April 10, 2024. This indicates that the trend has shifted lower and could be considered a sell signal. In of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CME declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for CME entered a downward trend on April 24, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Momentum Indicator moved above the 0 level on April 26, 2024. You may want to consider a long position or call options on CME as a result. In of 105 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CME advanced for three days, in of 335 cases, the price rose further within the following month. The odds of a continued upward trend are .
CME may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 74, placing this stock slightly better than average.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CME’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.855) is normal, around the industry mean (5.433). P/E Ratio (23.930) is within average values for comparable stocks, (35.241). CME's Projected Growth (PEG Ratio) (8.558) is very high in comparison to the industry average of (2.610). Dividend Yield (0.041) settles around the average of (0.030) among similar stocks. P/S Ratio (13.661) is also within normal values, averaging (105.216).
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
an operator of securities and commodity exchanges
Industry InvestmentBanksBrokers